antibody

Mouse Anti-Human TNFRSF13B

MBS690714

0.1 mg

490 USD

monoclonal

mouse

nonconjugated

[(9D22)]

western blot, immunohistochemistry

Antibody

Mouse Anti-Human TNFRSF13B

[TNFRSF13B]

[TNFRSF13B; CVID; TACI; CD267; CVID2; TNFRSF14B]

[tumor necrosis factor receptor superfamily member 13B; Tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor; tumor necrosis factor receptor superfamily, member 13B; Transmembrane activator and CAML interactor]

[TNFRSF13B]

[TNFRSF13B; TNFRSF13B; CVID; RYZN; TACI; CD267; CVID2; TNFRSF14B; TACI]

TR13B_HUMAN

Monoclonal

IgG1

[(9D22)]

Mouse

Human

293

Protein G chromatography

Lyophilized

Stability: Lyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20 °C for at least for six months without detectable loss of activity. Shipping: Ships with Blue Ice.

Western Blot (WB), Immunohistochemistry (IHC) - Formalin, Neutr

IHC (frozen): 1:20 - 1:200. WB: Use at 1:500-1000. Neutralization of Ligand/receptor interaction: Yes

Antibody Generation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human recombinant protein of TNFRSF13B extracellular domain (also called TACI). Antigen: Human recombinant TNFRSF13B EC domain. Reconstitution buffer: PBS (sterile)

Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml. Remarks: This antibody was selected for its ability to detect human TNFRSF13B.

TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily (TNFRSF). Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA both bind APRIL and BLyS/BAFF, members of the TNF superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Human and mouse TACI share 54% amino acid sequence identity.

6912694

NP_036584.1

NM_012452.2

O14836

31,816 Da

Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Intestinal Immune Network For IgA Production Pathway (128760); Intestinal Immune Network For IgA Production Pathway (128670); Primary Immunodeficiency Pathway (83125); Primary Immunodeficiency Pathway (537); Syndecan-2-mediated Signaling Events Pathway (138031); Syndecan-4-mediated Signaling Events Pathway (138064)

The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]

Function: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. Ref.6 Ref.7. Subunit structure: Binds TRAF2, TRAF5 and TRAF6. Binds the NH2-terminal domain of CAMLG with its C-terminus. Subcellular location: Membrane; Single-pass type III membrane protein. Tissue specificity: Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells. Involvement in disease: Immunodeficiency, common variable, 2 (CVID2) [MIM:240500]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.10Immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]: Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.10. Sequence similarities: Contains 2 TNFR-Cys repeats.

0.1 mg

490 USD